|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEL |
Gene summary for CEL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEL | Gene ID | 1056 |
| Gene name | carboxyl ester lipase | |
| Gene Alias | BAL | |
| Cytomap | 9q34.13 | |
| Gene Type | protein-coding | GO ID | GO:0001941 | UniProtAcc | B4DSX9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1056 | CEL | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.53e-05 | 1.33e-01 | 0.3859 |
| 1056 | CEL | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.86e-04 | 2.59e-01 | 0.2585 |
| 1056 | CEL | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.34e-96 | 1.89e+00 | 0.3005 |
| 1056 | CEL | CRC-1-8810 | Human | Colorectum | CRC | 5.83e-13 | 5.65e-01 | 0.6257 |
| 1056 | CEL | HTA12-15-2 | Human | Pancreas | PDAC | 2.78e-44 | -2.37e+00 | 0.2315 |
| 1056 | CEL | HTA12-23-1 | Human | Pancreas | PDAC | 5.00e-31 | -2.37e+00 | 0.3405 |
| 1056 | CEL | HTA12-25-1 | Human | Pancreas | PDAC | 1.86e-43 | -2.37e+00 | 0.313 |
| 1056 | CEL | HTA12-26-1 | Human | Pancreas | PDAC | 3.54e-52 | -2.37e+00 | 0.3728 |
| 1056 | CEL | HTA12-29-1 | Human | Pancreas | PDAC | 1.09e-119 | -2.37e+00 | 0.3722 |
| 1056 | CEL | HTA12-3-16 | Human | Pancreas | PDAC | 1.74e-10 | -2.37e+00 | 0.1553 |
| 1056 | CEL | HTA12-30-1 | Human | Pancreas | PDAC | 1.00e-11 | -2.37e+00 | 0.3671 |
| 1056 | CEL | HTA12-32-1 | Human | Pancreas | PDAC | 7.29e-14 | -1.93e+00 | 0.3624 |
| 1056 | CEL | HTA12-9-1 | Human | Pancreas | PDAC | 5.33e-67 | -2.30e+00 | 0.1532 |
| 1056 | CEL | HTA12-9-2 | Human | Pancreas | PDAC | 2.43e-26 | -5.78e-01 | 0.0835 |
| 1056 | CEL | HTA12-9-3 | Human | Pancreas | PDAC | 1.45e-36 | -2.37e+00 | 0.2045 |
| 1056 | CEL | 4347-EC | Human | Pancreas | PanIN | 4.74e-45 | -5.13e-01 | 0.0572 |
| 1056 | CEL | 4741-EC1 | Human | Pancreas | PanIN | 1.76e-02 | 1.12e-01 | 0.0223 |
| 1056 | CEL | 4741-EC2 | Human | Pancreas | PanIN | 1.33e-21 | 1.56e-01 | 0.0194 |
| 1056 | CEL | 181429 | Human | Pancreas | PDAC | 8.07e-20 | -2.37e+00 | 0.1416 |
| 1056 | CEL | 61354830 | Human | Pancreas | PDAC | 1.00e-11 | -2.37e+00 | 0.1458 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00606066 | Oral cavity | OSCC | tube closure | 52/7305 | 89/18723 | 1.59e-04 | 1.10e-03 | 52 |
| GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
| GO:00018388 | Oral cavity | OSCC | embryonic epithelial tube formation | 66/7305 | 121/18723 | 3.70e-04 | 2.26e-03 | 66 |
| GO:003514810 | Oral cavity | OSCC | tube formation | 78/7305 | 148/18723 | 4.82e-04 | 2.85e-03 | 78 |
| GO:00303248 | Oral cavity | OSCC | lung development | 91/7305 | 177/18723 | 5.18e-04 | 3.01e-03 | 91 |
| GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
| GO:00163315 | Oral cavity | OSCC | morphogenesis of embryonic epithelium | 77/7305 | 147/18723 | 6.63e-04 | 3.72e-03 | 77 |
| GO:00002456 | Oral cavity | OSCC | spliceosomal complex assembly | 45/7305 | 79/18723 | 9.13e-04 | 4.81e-03 | 45 |
| GO:00301779 | Oral cavity | OSCC | positive regulation of Wnt signaling pathway | 73/7305 | 140/18723 | 1.06e-03 | 5.46e-03 | 73 |
| GO:00721758 | Oral cavity | OSCC | epithelial tube formation | 69/7305 | 132/18723 | 1.32e-03 | 6.56e-03 | 69 |
| GO:004592710 | Oral cavity | OSCC | positive regulation of growth | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
| GO:00605416 | Oral cavity | OSCC | respiratory system development | 100/7305 | 203/18723 | 1.83e-03 | 8.60e-03 | 100 |
| GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
| GO:00219158 | Oral cavity | OSCC | neural tube development | 77/7305 | 152/18723 | 2.26e-03 | 1.00e-02 | 77 |
| GO:00604256 | Oral cavity | OSCC | lung morphogenesis | 29/7305 | 50/18723 | 5.01e-03 | 1.96e-02 | 29 |
| GO:00162463 | Oral cavity | OSCC | RNA interference | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
| GO:0021591 | Oral cavity | OSCC | ventricular system development | 18/7305 | 29/18723 | 1.00e-02 | 3.49e-02 | 18 |
| GO:001635810 | Oral cavity | OSCC | dendrite development | 113/7305 | 243/18723 | 1.00e-02 | 3.49e-02 | 113 |
| GO:00352646 | Oral cavity | OSCC | multicellular organism growth | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005612 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
| hsa005613 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
| hsa049728 | Colorectum | CRC | Pancreatic secretion | 32/1091 | 102/8465 | 7.86e-07 | 4.37e-05 | 2.96e-05 | 32 |
| hsa049729 | Colorectum | CRC | Pancreatic secretion | 32/1091 | 102/8465 | 7.86e-07 | 4.37e-05 | 2.96e-05 | 32 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEL | SNV | Missense_Mutation | rs755884951 | c.1709A>G | p.Glu570Gly | p.E570G | protein_coding | tolerated(0.12) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CEL | SNV | Missense_Mutation | c.1558N>T | p.Gly520Cys | p.G520C | protein_coding | tolerated(0.1) | probably_damaging(0.958) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
| CEL | SNV | Missense_Mutation | rs752422506 | c.1544N>A | p.Thr515Asn | p.T515N | protein_coding | tolerated(0.16) | benign(0.203) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| CEL | SNV | Missense_Mutation | rs746397927 | c.994N>A | p.Asp332Asn | p.D332N | protein_coding | deleterious(0.04) | possibly_damaging(0.562) | TCGA-E9-A1RC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| CEL | SNV | Missense_Mutation | novel | c.2149N>A | p.Val717Met | p.V717M | protein_coding | tolerated_low_confidence(0.08) | benign(0.154) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CEL | SNV | Missense_Mutation | rs760144206 | c.730G>A | p.Gly244Ser | p.G244S | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CEL | SNV | Missense_Mutation | rs201133893 | c.2171N>A | p.Gly724Glu | p.G724E | protein_coding | tolerated_low_confidence(1) | benign(0.001) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CEL | SNV | Missense_Mutation | rs202034862 | c.2173N>A | p.Ala725Thr | p.A725T | protein_coding | deleterious_low_confidence(0.02) | benign(0.219) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CEL | SNV | Missense_Mutation | rs202034862 | c.2173G>C | p.Ala725Pro | p.A725P | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.644) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| CEL | SNV | Missense_Mutation | c.832N>A | p.Ala278Thr | p.A278T | protein_coding | deleterious(0) | possibly_damaging(0.89) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | Bucelipase alfa | |||
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | ACTINOMYCIN D | 2016288 | ||
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | GENISTEIN | GENISTEIN | 10600647 | |
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | RESVERATROL | RESVERATROL | 16099206 | |
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | SIMVASTATIN | SIMVASTATIN | 16955753 | |
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | GELDANAMYCIN | GELDANAMYCIN | 11104697 | |
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | BILE SALT STIMULATED LIPASE | |||
| 1056 | CEL | CELL SURFACE, DRUGGABLE GENOME, ENZYME | Taurocholic Acid |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |